Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma
Keywords:
Nivolumab, Elderly patients, Malign melanoma, Anti pd-1Abstract
Aim: This study aimed to analyse the clinical characteristics, effectiveness and safety of nivolumab monotherapy in patients aged≥ 65 years with metastatic melanoma.
Materials and Methods: This study involved patients aged ≥65 years who were diagnosed with metastatic cutaneous or mucosal melanoma. Patients with BRAF wild type, ECOG performance status 0-1, and who had previously received one line of chemotherapy were included, irrespective of PD-L1 expression. The study analyzed PFS, OS, and adverse event profiles.
Results: Twenty-one patients, with a median age of 70, were analysed in the study. The median PFS for nivolumab as second-line therapy in elderly patients was 3.5 months (95% CI, 1.5 to 5.6 months), while the median OS was 14.5 months (95% CI, 10.3 to 18.6 months). The most common grade 1-2 adverse events were anemia (66.7%) and serum creatinine increase (23.8%). Additionally, the rate of grade 3-4 adverse events due to all causes was 28.6%. There was no grade 5 adverse event.
Conclusion: Nivolumab is effective and safe as second-line therapy in patients aged ≥65 years with metastatic melanoma. It is a tolerable and effective treatment choice for elderly patients who cannot received nivolumab in first line therapy.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Annals of Medical Research

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
CC Attribution-NonCommercial-NoDerivatives 4.0